Yemaachi Biotech

Lucence and Yemaachi Launch the AMBER Study to Detect and Characterize Genomic Alterations in Breast Cancer in Women in Africa and Expand Liquid Biopsy Access

PALO ALTO, Calif. & ACCRA, Ghana–(BUSINESS WIRE)–Lucence, a precision oncology company using liquid biopsy to bring clarity to cancer care, and Yemaachi Biotech, a cancer research company based in Accra, Ghana, announced today that they are collaborating on a study to better characterize and understand the genomics of breast cancer in women of African descent.